Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Humacyte Inc (NQ: HUMA )

5.780 +0.520 (+9.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Humacyte Inc

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
10 Best Stock Traders In Congress In 2023 (Spoiler: Nancy Pelosi Is Back On The List)
A new report highlights the 10 members of Congress who profited the most from the stock market in 2023. 
Via Benzinga
Tommy Tuberville Lost On Tesla Trade, Could Win Big On US Steel Trade: A Look At The Congress Trades Raising Eyebrows
Senator Tommy Tuberville has been actively trading United State Steel stock and options ahead of a proposed buyout. 
Via Benzinga
Humacyte: Q3 Earnings Insights
Via Benzinga
Humacyte's Earnings: A Preview
Via Benzinga
Humacyte Earnings Preview
Via Benzinga
Recap: Humacyte Q1 Earnings
Via Benzinga
Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma
From Humacyte, Inc
Via GlobeNewswire
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
Via ACCESSWIRE
Humacyte Third Quarter 2023 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023
From Humacyte, Inc
Via GlobeNewswire
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model
-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease- 
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present at the Cantor Global Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023
From Humacyte, Inc
Via GlobeNewswire
Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries
Humacyte Inc (NASDAQ: HUMA) released topline results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair, showing that the HAV had higher rates of patency and... 
Via Benzinga
Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Gainers AgileThought, Inc. (NASDAQ: AGIL) shares rose 72.5% to $0.2160 in pre-market trading after declining 12% on Monday. 
Via Benzinga
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day off with a breakdown of the biggest pre-market stock movers worth watching on Tuesday morning! 
Via InvestorPlace
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET
Virtual Webinar to Include Key Opinion Leader Perspectives on the Potential of the HAV in Vascular Trauma Repair 
From Humacyte, Inc
Via GlobeNewswire
Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference
-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage- 
From Humacyte, Inc
Via GlobeNewswire
Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate
The public's scrutiny of Congress members trading stocks and options has intensified as websites and social media increasingly broadcast the disclosed data. 
Via Benzinga
Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 300 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Humacyte Second Quarter 2023 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Earnings Scheduled For August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Via Benzinga
Earnings Scheduled For May 12, 2023
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.